The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 67)
Research Grant, 2017
Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may be that the activity of the enzymes (chemicals that increase chemical reactions) encoded by these genes is increased (as suspected in LRRK2) or reduced (as suspected in GBA). The purpose of this stud...
LRRK2 Biology Consortium, 2017
Development of Nanobodies as Novel Tools to Characterize LRRK2 as a Potential Drug Target for Parkinson's Disease
Several genes play a crucial role in Parkinson's disease (PD). The most common genetic cause of PD is mutations in the gene encoding LRRK2, a very large and complex protein with different enzyme (accelerates chemical reactions) functions. Targeting the multiple enzymatic functions of LRRK2 represents a very attractive approach for designing novel therapeutics for PD that requires ...
Target Advancement Awards, 2017
Galectins proteins (proteins that bind sugar molecules) mediate the cellular response to endocytic (transfer of molecules to cells) vesicles (storage sacks) ruptured by amyloid proteins (protein clumps), such as alpha-synuclein (sticky protein that accumulates in the brains of those with Parkinson's). We have observed that vesicles containing alpha-synuclein either fuse with simil...
Researchers: Edward M. Campbell, PhD
Therapeutic Pipeline Program, 2016
Cell replacement therapies for Parkinson's disease (PD) propose to replace the lost dopaminergic neurons in the brain. Transplanted fetal dopamine neurons have provided remarkable recovery in some PD patients and can survive and function for decades. More recently, the field has evolved from this innovative but complex fetal dopamine cell transplantation method t...
Researchers: Ole Isacson, MD, PhD
Priority Target Award, 2016
People who have mutations in the GBA1 gene have a higher chance of developing Parkinson's disease (PD) but it is unclear why. We found that GBA1 mutations affect the cellular ability to clear proteins by disrupting regulation of the lysosomes. The lysosomes are responsible for recycling cellular components and inability to do this function can lead to neuronal death. Both levels an...
Researchers: Ola A. Awad, MBBCh, MSc, PhD